Recombinant Crisantaspase (OP-02)
Not specified (likely leukemia)
DevelopmentExclusive supply agreement secured
Key Facts
Indication
Not specified (likely leukemia)
Phase
Development
Status
Exclusive supply agreement secured
Company
About Ohara Pharmaceutical
Japanese pharma company developing innovative and generic drugs for oncology, hepatology, and CNS disorders.
View full company profile